Medostatin (Lovastatin)

Lovastatin inhibits the enzyme HMG‑CoA reductase, the rate‑limiting step in hepatic cholesterol synthesis. This reduction in cholesterol production triggers an increase in LDL‑receptor expression on liver cells, enhancing removal of LDL particles from the bloodstream and lowering plasma cholesterol.

The appropriate dose of Medostatin is determined by the prescribing clinician based on the patient’s cholesterol levels, overall risk profile, and any concomitant medications. Dosage adjustments are made according to clinical response and laboratory monitoring.

Medostatin is classified as pregnancy category X, meaning it is contraindicated in pregnancy because of potential fetal harm. It is also not recommended while breastfeeding, as lovastatin can be excreted in breast milk and may affect the infant.

To place an order, submit an enquiry on the Medostatin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Medostatin (lovastatin) is a first‑generation statin with a well‑established efficacy profile. Compared with newer agents such as rosuvastatin or atorvastatin, lovastatin may require higher doses to achieve similar LDL‑cholesterol reductions, but it remains a cost‑effective option for many patients when tolerated.

Medostatin should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, heat and direct sunlight to maintain potency throughout the shelf life.

Medostatin is taken orally, usually once daily with the evening meal to improve absorption. The tablet should be swallowed whole with a glass of water; it should not be crushed, chewed, or split unless specifically instructed by a healthcare professional.

The most serious risks include rhabdomyolysis (severe muscle breakdown), significant liver injury, and rare hypersensitivity reactions such as anaphylaxis. Patients should report unexplained muscle pain, dark urine, jaundice, or signs of an allergic reaction promptly.

Medostatin should not be used by individuals who are pregnant, nursing, have active liver disease, or have a known hypersensitivity to lovastatin or any component of the formulation. It is also contraindicated when taken with certain strong CYP3A4 inhibitors.